Scully B E, Neu H C
Arch Intern Med. 1984 Jan;144(1):57-62. doi: 10.1001/archinte.144.1.57.
Ceftazidime, a beta-lactamase stable cephalosporin, was administered to 57 patients. Substantial underlying disease was present in the majority of patients, and 50% were in critical or poor condition. Ceftazidime inhibited all initial isolates of Enterobacteriaceae at 8 mg/L or less, regardless of resistance to other antibiotics and the majority of Pseudomonas aeruginosa at 12 mg/L or less. The mean serum level after infusion of 1 g during 30 minutes was 62 mg/L. Overall clinical response was 84%, and the bacteriological response was 72% excluding cystic fibrosis patients. No major adverse effects were encountered. Resistance developed in Pseudomonas from patients with cystic fibrosis and in Enterobacter from two other patients. Ceftazidime was an effective, safe therapy for serious infection due to multiply resistant Pseudomonas and other aerobic gram-negative bacilli including aminoglycoside-resistant Serratia and Klebsiella.
头孢他啶是一种对β-内酰胺酶稳定的头孢菌素，应用于57例患者。大多数患者存在严重的基础疾病，50%的患者病情危急或较差。头孢他啶能抑制所有初始分离的肠杆菌科细菌，浓度在8mg/L及以下，无论其对其他抗生素的耐药情况如何，并且能抑制大多数铜绿假单胞菌，浓度在12mg/L及以下。在30分钟内输注1g后，平均血清浓度为62mg/L。总体临床有效率为84%，细菌学有效率为72%（不包括囊性纤维化患者）。未出现重大不良反应。囊性纤维化患者的铜绿假单胞菌以及另外两名患者的肠杆菌属出现了耐药。头孢他啶是治疗由多重耐药铜绿假单胞菌和其他需氧革兰氏阴性杆菌（包括耐氨基糖苷类的沙雷菌属和克雷伯菌属）引起的严重感染的一种有效、安全的疗法。
